NCT05966064View on ClinicalTrials.gov

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)

PHASE4RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Fibrous DysplasiaMcCune Albright Syndrome
Interventions
DRUG

Denosumab 120 Mg/1.7 Ml Inj

Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label

DRUG

Placebo

placebo randomized at baseline and after 3 months

Trial Locations (1)

Unknown

RECRUITING

Leiden University Medical Center, Leiden

All Listed Sponsors
lead

Natasha Appelman-Dijkstra

OTHER